Summary:
- The article reports the final overall survival results from the TROPION-Breast01 Phase 3 trial, which evaluated datopotamab deruxtecan (Dato-DXd) in patients with metastatic hormone receptor (HR)-positive, HER2-low or HER2-negative breast cancer.
- The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival for patients treated with Dato-DXd compared to the standard of care chemotherapy.
- The safety profile of Dato-DXd was consistent with previous studies, and the drug was generally well-tolerated by patients, making it a promising new treatment option for this patient population.